Ebola Contract Drives 70 Percent Rise in Tekmira's Q1 Revenues; Supports LNP Scale-up | GenomeWeb

By Bernadette Toner

Tekmira this week reported a 70 percent increase in first-quarter revenues, driven by a US government contract to develop an RNAi therapeutic to treat Ebola virus infection.

Officials said in a conference call to discuss the company's first-quarter financial results that under the Ebola contract, Tekmira has been able to scale up its lipid nanoparticle technology to support late clinical development and therapeutic manufacturing.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: global genetic diversity map, and more.

The Nuffield Council on Bioethics identifies ethical questions to explore surrounding genome editing.

In a blog post, Brigham and Women's Hospital's Robert Green discusses "predispositional personal genome sequencing."

Stat News reports that there's muted opposition to the Kuwaiti DNA database law.